Genitourinary Cancer
Feature
Maintaining cancer care in the face of COVID-19
Oncologists are moving cancer patients to other hospitals, reevaluating the need for cancer treatments, and embracing telemedicine to protect...
Conference Coverage
CARAVAGGIO expands DOAC pool in cancer-related VTE
From the Journals
SABR slashes progression of advanced prostate cancer
When compared with observation, stereotactic ablative radiotherapy decreased disease progression three-fold in patients with oligometastatic...
Commentary
Perspective from the heartland: Cancer care and research during a public health crisis
Dr. Alan P. Lyss examines how the COVID-19 pandemic has and will affect cancer care and research.
Latest News
Week-old COVID-19 urology guidelines already outdated
From the Journals
Genomic prostate score does not improve risk assessment
Latest News
Cancer care and COVID-19 in Seattle, the first U.S. epicenter
Feature
How is oncology adapting to COVID-19?
Feature
Disruptions in cancer care in the era of COVID-19
Conference Coverage
Lymphopenia linked to worse response in RCC, bladder cancer patients on checkpoint inhibitors
ORLANDO – Patients with lower pretreatment absolute lymphocyte counts and higher neutrophil-lymphocyte ratios were less likely to respond to...
From the Journals
Antidepressant could treat recurrent prostate cancer
A quarter of patients achieved a PSA reduction of at least 30% from baseline, and 10% had a reduction of at least 50% from baseline.